Latest Strategy News

Page 370 of 917
Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.
Ada Torres
Ada Torres
29 Aug 2025
OMG Group Limited reported a robust 63.3% revenue increase to $4.13 million in FY2025, driven by strategic acquisitions and expanded retail partnerships. The company also narrowed its losses by 29%, setting the stage for sustained growth in FY2026.
Victor Sage
Victor Sage
29 Aug 2025
Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.
Ada Torres
Ada Torres
29 Aug 2025
Seafarms Group Limited reported a reduced loss of $11.7 million for FY2025, despite a 43% drop in revenue and ongoing legal challenges surrounding Project Sea Dragon. Production setbacks from flooding and subdued market demand weighed heavily on results.
Ada Torres
Ada Torres
29 Aug 2025
Spectur Limited reported a 6% revenue increase to $8.7 million and slashed its net loss by 70% to $779,000 in FY25, driven by operational restructuring and a shift toward recurring revenue streams.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Coventry Group Ltd reported a 1.7% revenue decline and a 40.9% drop in EBITDA for FY25, prompting a major restructuring and a bullish FY26 earnings target above $20 million.
Victor Sage
Victor Sage
29 Aug 2025
Coventry Group reports a challenging FY25 with a statutory loss driven by ERP implementation costs and asset impairments, while setting ambitious EBITDA targets for FY26 under refreshed leadership.
Victor Sage
Victor Sage
29 Aug 2025
Coventry Group Ltd reported a challenging FY25 with a 1.7% revenue decline and a 40.9% drop in underlying EBITDA, culminating in a $29.6 million net loss. The company is now targeting over $20 million EBITDA in FY26 through aggressive cost reductions and operational recalibration.
Victor Sage
Victor Sage
29 Aug 2025
Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.
Ada Torres
Ada Torres
29 Aug 2025
Mustera Property Group reports an 82% plunge in revenue and a net loss of $2.6 million for the year ended June 2025, marking a stark reversal from the prior year’s profit.
Eva Park
Eva Park
29 Aug 2025
Assetora Limited reports a dramatic 54% reduction in net losses and strengthens its balance sheet, setting the stage for growth with the reopening of the DomaCom Fund.
Claire Turing
Claire Turing
29 Aug 2025
Assetora Limited reported a reduced loss of $3.35 million for FY2025 despite an 18% revenue decline, focusing on capital raising and fund growth to stabilize operations.
Claire Turing
Claire Turing
29 Aug 2025